Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096950 | 0.91 | MAPK14 (0.42) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4096944 | 0.91 | MAPK14 (0.42) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4084479 | 0.91 | MAPK14 (0.42) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4096956 | 0.91 | MAPK14 (0.42) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4090017 | 0.83 | MAPK14 (0.41) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5991023 | 0.79 | GSK3B (0.43) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4092426 | 0.79 | GSK3B (0.43) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4090526 | 0.79 | GSK3B (0.43) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4096958 | 0.77 | PARP1 (0.40) | GSK3BMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4095014 | 0.76 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | claimed |
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | GSK3B 64/4885MAPK14 1220/4885MAPK13 300/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | GSK3B 86/4885MAPK14 964/4885MAPK13 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.